No Data
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Currently, there is no plan to divest Tasly Pharmaceutical Group's non-traditional chinese medicine business.
China Resources Sanjiu Medical & Pharmaceutical stated in an investor relations event on August 8 that Tasly Pharmaceutical Group's pipeline of traditional Chinese medicine as the core, with biological and chemical medicine as the auxiliary, is complementary to the business layout of modern traditional Chinese medicine. As we expand the modern traditional Chinese medicine business, we will also specialize in biological and chemical medicine, forming a pipeline complementary business layout. We recognize the pipeline layout of Tasly Pharmaceutical Group and will mutually empower each other in the future to promote the stable leading position of Tasly Pharmaceutical Group in innovative research and development of traditional Chinese medicine. Currently, there is no plan to divest non-traditional Chinese medicine business of Tasly Pharmaceutical Group.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Tasly Pharmaceutical Group is an excellent enterprise that the company has long-term attention to, with a competitive advantage in the entire industry chain.
On August 8th, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated in an investor relations event that since the beginning of the 14th Five-Year Plan, the company has been focused on the strategic goal of becoming a leading enterprise in the industry, adhering to the dual driving force of "brand + innovation", continuously improving its business layout, and highly concerned about opportunities to integrate high-quality resources in the industry chain. Tasly Pharmaceutical Group is an excellent enterprise that the company has long been concerned about and has a competitive advantage in the entire industry chain. China Resources Sanjiu Medical & Pharmaceutical is a leading enterprise in the traditional Chinese medicine industry chain, and the strategic layout of the two sides is highly matched. Therefore, the company is very pleased to have such an opportunity to cooperate with Tasly Pharmaceutical Group in terms of equity.
Zhejiang Canaan Technology (300412.SZ): the company's clients include Tasly Pharmaceutical Group, China Resources, etc.
On August 8th, Gelunhui reported that Zhejiang Canaan Technology (300412.SZ) stated on their investor interaction platform that the majority of their customers are well-known international and domestic companies in the pharmaceutical industry, including Tasly Pharmaceutical Group and China Resources.
Hong Kong stocks' abnormal movement: Chinars Pharma (03320) rose another 3% with a premium acquisition of 28% equity of Tasly Pharmaceutical Group. Institutions have raised the company's revenue forecast.
Chinarese Pharma (03320) has risen by more than 3%, as of press time, up 3.3% to HKD 5.63, with a turnover of 39.2174 million HKD.
CR Sanjiu Medical to Buy 28% Stake in Tasly Pharma for Over 6 Billion Yuan; Tasly Shares Down 4%
Chinacores pharma: China Resources Sanjiu Medical & Pharmaceutical plans to spend about 6.212 billion yuan to acquire 28% equity of Tasly Pharmaceutical Group.
China Resources Pharma (03320) announced that on August 4, 2024, China Resources Sanjiu entered into a share purchase agreement with the seller. Accordingly, China Resources Sanjiu has conditionally agreed to purchase and the seller has conditionally agreed to sell a total of 0.418 billion shares of Tasly Pharmaceutical Group (equivalent to 28% equity of Tasly Pharmaceutical Group as at the date of this announcement) at a proposed price of RMB 14.85 per share, or a total consideration of approximately RMB 6.212 billion. After completion, China Resources Sanjiu will hold a 28% stake in Tasly Pharmaceutical Group and become its largest shareholder, while Tasly Pharmaceutical Group will serve as a non-wholly owned subsidiary of the company.
No Data
